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To help prevent anaemia, it is a requisite for blood donors to undergo a haemoglobin test to ensure levels
are not too low before donation. It is therefore important to have an accurate testing device and strategy
to ensure donors are not being inappropriately bled. A recent study in blood donors used a selective
testing strategy where if a donor’s haemoglobin level is below the level required for donation, then another
reading is taken and if this occurs again, a third and final reading is used. This strategy can reduce the
average number of readings required per donor compared to taking three measurements for all donors.
However, the final decision-making measurement will on average be higher than a single measurement.
In this paper, a selective testing strategy is compared against other strategies. Individual-level biases are
derived for the selective strategy and are shown to depend on how close a donor’s true haemoglobin level
is to the donation threshold and the magnitude of error in the testing device. A simulation study was
conducted using the distribution of haemoglobin levels from a large donor population to investigate the
effects different strategies have on population performance. We consider scenarios based on varying the
measurement device bias and error, including differential biases that depend on the underlying haemoglobin
level. Discriminatory performance is shown to be affected when using the selective testing strategies,
especially when measurement error is large and when differential bias is present in the device. We recommend
that the average of a number of readings should be used in preference to selective testing strategies if
multiple measurements are available.
Key words: Blood donation; Diagnostic performance; Multiple measurements; Selective testing;
Simulation study;
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1 Introduction
Blood donations are an integral part of many health services across the world (http:
//www.who.int/mediacentre/factsheets/fs279/en). To help prevent anaemia, it
is a requisite for blood donors to undergo a haemoglobin (Hb) test to ensure levels are not too
low before donation. In most European countries the Hb threshold levels for donation are set at
135g/L for males and 125g/L for females. A number of point-of-care screening tests are available,
including measuring Hb in capillary or venous blood samples, for example with a HemoCue R© device
(http://www.hemocue.com/en/solutions/hematology) or using a non-invasive device
that uses technology such as spectroscopy to measure Hb levels without taking a blood sample. Whilst
the measuring performance of a device is important, the strategy employed when using these devices is
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arguably as important. Singh et al. (2015) and Hiscock et al. (2014) suggest using an average of multiple
Hb measurements to increase precision in the estimated Hb level and therefore increase accuracy in the
decision of whether the donor should donate or not.
Recently in a paper by Baart et al. (2016), a strategy was used such that if a donor is tested and their
measured Hb level is below a sex-specific donation threshold required for donation, then a second
measurement should be taken and if that is below the threshold then a third measurement should be taken.
The final measurement taken becomes the decision-making measurement for the donor and is used to
determine whether they should donate. Such a strategy can reduce the average number of measurements
taken per donor compared with measuring all donors three times (and using the average to make a
decision), and can result in fewer deferrals for donors who are close to the donation threshold. The number
of measurements taken depend on the donor’s measured Hb level. For example a low-risk donor with high
Hb may need to be measured only once to ensure that they can donate above the threshold, whilst a donor
close to the donation threshold might be measured at most three times. Therefore in a general population,
fewer measurements are taken compared with taking three measurements for all donors and the average
time needed to measure a donor’s Hb would be reduced.
However, assessing the performance of the testing device is compromised by the use of the testing strategy.
The selective testing strategy described is akin to what previous papers have described as “sequential
testing”, which could lead to sequential testing bias. For example, in clinical trials, decisions to continue
or not are made at the end of each trial phase and can lead to sequential biases that affect evidence
syntheses as shown by Kulinskaya et al. (2016) and Denne (2000). Similar problems arise in group
sequential clinical trials where an interim decision to stop or extend one or more trial arm can bias the final
treatment effect estimate, as shown by Whitehead (1986), Liu et al. (2004), Koopmeiners et al. (2012)
and Choodari-Oskooei et al. (2013). The selective testing strategy described for blood donors presents an
interesting extension of a sequential bias problem where decisions to proceed (take a further measurement)
or not are made for each individual donor.
A selective testing strategy in blood donor studies may have implications on the individual-level bias
which may also have implications exhibited at the population level, such as an increase in the number
of donors who are bled below the Hb threshold. The reported sensitivity and specificity of a device may
also be compromised if such a testing strategy is implemented, and may partly be the reason why a recent
study of a number of devices estimated very low sensitivities ranging from 3.5% to 37% (Baart et al.,
2016). Studies by Pagliaro et al. (2014), Clippel et al. (2017) and Ahankari et al. (2016) did not highlight
the use of this strategy and showed higher sensitivity levels ranging from 13% to 63%. To investigate
this further we quantify the bias of a selective testing strategy as a function of a donor’s true Hb level
and the measurement error in the device at the individual-level, and explore in a simulation study the
effect the selective testing strategy has on the population-level by measuring statistics such as the bias in
estimating the mean Hb, and the sensitivity and specificity of the decision-making measurement. These
are of particular interest to a blood donation service as the bias can inform whether the device is under
or overestimating relative to a “gold-standard”, whilst the sensitivity and specificity can determine the
proportion of donors correctly deferred or bled.
In this paper we compare the selective testing strategy to a strategy that uses an average of a pre-defined
number of measurements and a strategy that uses selective testing based on the average of previous
measurements to define the decision-making measurement. The testing strategies are presented formally
in Section 2. In Section 3, the bias of the selective strategies for a given range of true Hb levels close to
the Hb donation threshold is quantified. Section 4 describes a simulation study for a population of donors
where the overall bias in the reported mean Hb level, coverage of the confidence intervals, variance, and
the sensitivity and specificity of the testing strategies in identifying donors below and above the donation
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threshold are estimated. Finally in Section 5, recommendations are made regarding the different strategies
for repeat testing of Hb levels.
2 Testing Strategies
The first strategy uses selective testing (ST) to obtain a final decision-making measurement for each donor.
Given the results of an initial Hb measurement, a second measurement is taken if and only if the initial
measurement is below a sex-specific donation threshold. A third measurement is taken if and only if the
second measurement is below the sex-specific donation threshold and this continues up to a maximum
of K measurements. The final measurement that is taken is used to define the donor’s decision-making
measurement, which is used for determining whether the individual is bled or deferred. When K = 1 this
strategy reduces to a single measurement test. The second strategy uses the average of K measurements
for all donors (labelled the Average Measurements (AM) strategy), where K is pre-specified. The third
strategy is similar to the selective testing strategy, which takes a new measurement if and only if the
previous measurement is below the threshold, but an average of the measurements taken is used to
define the donor’s final decision-making measurement, and is therefore a combination of the ST and
AM strategies (labelled the STAM strategy). The STAM strategy was investigated because, like the ST
strategy, it benefits from needing on average fewer measurements per donor than the AM strategy but may
also be less biased than the ST strategy.
Let A(K)i , B
(K)
i and C
(K)
i represent the decision-making Hb level from the ST, AM and STAM testing
strategies, respectively, for the ith donor using a maximum of K measurements and let yik be the kth
(k = 1, ...,K) measurement for the ith (i = 1, ..., n) donor. Let T denote the Hb threshold for donation
(e.g. 135g/L in males). Then the three key testing strategies are formally defined as follows:
(ST) Selective testing strategy with a maximum of K measurements:
A
(K)
i ∼

yi1 if yi1 ≥ T
yi2 if yi1 < T and yi2 ≥ T
...
yiK−1 if yi1 < T , ... , yiK−2 < T and yiK−1 ≥ T
yiK if yi1 < T , ... , yiK−1 < T
(AM) Average of K measurements:
B
(K)
i =
1
K
(yi1 + ...+ yiK)
(STAM) Selective testing and averaging strategy with a maximum of K measurements:
C
(K)
i ∼

yi1 if yi1 ≥ T
1
2
(yi1 + yi2) if yi1 < T and yi2 ≥ T
...
1
K − 1(yi1 + ...+ yiK−1) if yi1 < T , ... , yiK−2 < T and yiK−1 ≥ T
1
K
(yi1 + ...+ yiK) if yi1 < T , ... , yiK−1 < T
Seven variations of the above testing strategies are discussed in this paper; a selective testing strategy with
a maximum of two or three measurements, an averaging strategy with one, two or three measurements, and
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the selective testing and averaging strategy with a maximum of two or three measurements. These will be
denoted as ST2, ST3, AM1, AM2, AM3, STAM2 and STAM3.
3 Bias of testing strategies under Normally distributed measurement error
3.1 Derivation of individual-level bias
In this section the individual-level bias of the decision-making Hb level for each testing strategy under a
Normal measurement error model is quantified. Suppose that a point-of-care Hb test device is unbiased so
that, given a true Hb level µi from individual i, observed measurements can be described as realisations
from a Normal distribution with mean µi and standard deviation σe. Since repeat measurements are taken
together over a short space of time we shall assume that the variation in Hb levels within an individual is
due to measurement error from the testing device and not from changes in the underlying phenotype, as
might be the case for example with blood pressure. For an individual i, let each measurement, conditional
on µi, be independent and identically distributed with
Yik ∼ N(µi, σ2e) ; k = 1, ...,K.
Therefore for all testing strategies the Yik are assumed independent from one another.
For the AM testing strategy withK measurements it is trivial to see that the estimated Hb level is unbiased:
E
(
B
(K)
i
)
= E
(∑K
k=1 Yik
K
)
= µi
For the ST testing strategy, and dropping the subscript i from this point onwards, E
(
A(K)
)
and the bias
E
(
A(K)
) − µ can be obtained as follows. First focussing on the case where the maximum number of
measurements is two (ST2) to obtain E
(
A(2)
)
:
E(A(2)) = E(Y1|Y1 ≥ T )p(Y1 ≥ T ) + E(Y2|Y1 < T )p(Y1 < T )
Note that the first term of the equation is a truncated normal (for y1) whilst the second part is a conditional
normal (of y2 given Y1). To make calculations simpler further on, each measurement Yk is standardised
such that Zk = Yk−µσe ∼ N(0, 1) ; k = 1, ...,K.
Then the expectation of A(2) can be written as
E(A(2)) = [σe E(Z1|Z1 ≥ Tz) + µ]p(Z1 ≥ Tz) + [σe E(Z2|Z1 < Tz) + µ]p(Z1 < Tz)
where Tz = T−µσe
Using results of the truncated and conditional normal distributions as shown by Maddala (1983),
E(Z1|Z1 > a) = φ(a)1−Φ(a) and E(Z1|Z2 < a) = −ρ φ(a)Φ(a) , where Z1 and Z2 are both standard normal, φ(·)
and Φ(·) are the standard Normal density and distribution functions, respectively, and ρ is the correlation
between Z1 and Z2. Since each yk, and therefore each zk, are independent from one another, conditional
on µ, and the correlation ρ = 0, the expectation for A(2) is therefore:
E(A(2)) =
(
σe
φ(Tz)
1− Φ(Tz) + µ
)
(1− Φ(Tz)) + µΦ(Tz) = µ+ σeφ(Tz)
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Working through the strategy ST3 in a similar manner, the expectation is:
E
(
A(3)
)
= E(Y1|Y1 ≥ T ) p(Y1 ≥ T )
+ E(Y2|Y1 < T , Y2 ≥ T ) p(Y1 < T , Y2 ≥ T )
+ E(Y3|Y1 < T , Y2 < T ) p(Y1 < T , Y2 < T )
which due to independence simplifies to:
E
(
A(3)
)
= E(Y1|Y1 ≥ T ) p(Y1 ≥ T )
+ E(Y2|Y2 ≥ T ) p(Y1 < T )p(Y2 ≥ T )
+ E(Y3) p(Y1 < T )p(Y2 < T )
Standardising and using results of the truncated and conditional normal distributions, as before, results in
the following equation for the expectation of the ST3 strategy:
E
(
A(3)
)
= µ+ σeφ(Tz)(1 + Φ(Tz)) ≥ µ
The bias in the Hb level estimated from the ST strategy is given by E
(
A(K)
) − µ. The individual-level
bias for ST2 and ST3 is therefore:
Bias
(
A(2)
)
= σeφ(Tz) ≥ 0
Bias
(
A(3)
)
= σeφ(Tz)(1 + Φ(Tz)) ≥ 0
Generalising the amount of bias for any selective testing strategy where the maximum number of
measurements is K gives the following result:
Bias
(
A(K)
)
= σeφ(Tz)
(
K−2∑
k=0
Φ(Tz)
k
)
for K ≥ 2
In a similar manner, generalising the amount of bias for any selective testing and averaging (STAM)
strategy with a maximum of K measurements gives the following result:
Bias
(
C(K)
)
= σeφ(Tz)
(
K−2∑
k=0
1
k + 2
Φ(Tz)
k
)
for K ≥ 2
3.2 Calculation of individual-level bias for different µ and σe
To understand the effects of how the individual-level bias for the selective testing strategies ST2, ST3,
STAM2 and STAM3 change with varying levels of measurement error, σe, and underlying Hb level µ,
the bias was plotted against the difference in µ from the Hb threshold. Figure 1 shows the bias at the
individual-level as the measurement error is increased from 1g/L, to 6g/L, to 11g/L.
The maximum amount of bias exhibited for testing strategies ST2 and STAM2 is equivalent to σe (φ(0))
and σe
(
1
2φ(0)
)
respectively, approximately 0.40σe and 0.20σe, and occurs when the true Hb level is at
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the threshold. In contrast, the maximum bias for ST3 and STAM3 is approximately 0.62σe and 0.27σe
respectively. To determine the location of the maximum bias, a numerical approximation was calculated
by plotting the bias for multiple values of σe and using its maximum to determine the difference from
the Hb threshold for when this occurs. For ST3 and STAM3 respectively, these were −0.25σe g/L and
−0.19σe g/L from the threshold.
4 Simulation Study
4.1 Data Generation
A simulation study was conducted in R to assess the bias and coverage in estimating the population mean
Hb level, and the diagnostic performance of the testing strategies on a population with an Hb distribution
typical of presenting blood donors. This was done to understand what effect the individual-level biases
have on blood donations in a general population. The data for the simulation study was generated by
performing 1000 simulations, with 2500 donors in each simulation. The number of donors was chosen to
closely represent the number of donors analysed in previously published medium-sized Hb-testing studies
such as those by Baart et al. (2016), Pagliaro et al. (2014) and Ziemann et al. (2011).
For each donor, their true Hb level µi was drawn from a Normal distribution that aimed to approximate
a distribution of Hb values measured using a “gold standard” haematology analyser in 13,413 males and
15,081 females presenting donors in the COMPARE study (www.comparestudy.org.uk). The
empirical mean and standard deviation from the COMPARE study was 151g/L and 10g/L for males and
135g/L and 10g/L for females, respectively, whilst the prevalence of low Hb in the population was 5.2%
for males and 13.3% for females (using the standard thresholds of <135g/L for males and <125g/L for
females). A simulated data set using the empirical mean and standard deviation was generated. Since the
distributions of Hb seen in the COMPARE population of donors are fairly similar in shape for either sex,
results in the simulation study were shown for males only. An approximation of Hb values was used due
to the confidentiality of data.
Three point-of-care Hb measurements were independently drawn for each donor from a Normal
distribution with mean µi + bi and measurement error σe, where bi represents bias in the measurement
device for the ith donor. Measurements based on each of the seven strategies described in Section 2 were
obtained and the difference between the measurement based on each strategy and the donor’s true Hb level
was calculated. The bias of the mean estimated Hb level in the population under each testing strategy was
calculated for each simulation and the mean bias and coverage of the 95% confidence intervals for the
mean Hb level were summarised over the simulations.
The sensitivity, defined as the proportion of donors with a “gold-standard” measurement below the
threshold who also had a decision-making measurement below the threshold, and the specificity, defined
as the proportion of donors with a “gold-standard” measurement above the threshold who also had
a decision-making measurement above the threshold, were calculated for each testing strategy. The
confidence intervals for sensitivity and specificity were calculated using a binomial exact test. The area
under the receiver operating characteristic curve (AUC) was used to quantify the discriminatory ability
for each strategy. An empirical curve was generated by varying the Hb threshold in increments of 1g/L,
whilst the AUC was calculated using the trapezoidal rule (Robin et al., 2011). Performance metrics were
then averaged across the 1000 simulations.
c© 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
Biometrical Journal 52 (2010) 61 7
4.2 Scenarios
The simulation study was conducted for different values of the measurement error σe. A plausible range
was chosen using data on 3704 male donors in COMPARE who had three repeated measurements of Hb
at the same visit. The mean measurement error in this population was 5.5g/L (standard deviation 4.6g/L).
Hence the measurement error in the simulation study varied from 1g/L up to 11g/L. Each of the repeated
measurements were automatically taken seconds apart from one another and so within-person variability
of Hb levels can be assumed to be negligible. The main scenario considered unbiased measurement
devices (e.g bi = 0 ∀i). Three further scenarios that introduced bias in the measurement device in different
forms were conducted.
The first scenario considered systematic bias in the measurement device such that bi = c for all i, where
c was allowed to vary between -2g/L and +2g/L. Hence the device’s bias is constant for all individuals
and independent from an individual’s Hb measurement. This aimed to show how the sensitivity and
specificity of a point-of-care device can be affected by systematic bias. The second scenario varied
the amount of bias in the testing device between individuals. This was done to mimic what might be
experienced in a real world scenario, such as temperature changes that might affect day-to-day, and hence
donor-to-donor, variation. The device bias for each donor was simulated from a Normal distribution such
that bi ∼ N(0, σ2b ), where σb was varied between 0g/L and 5g/L. Note σb = 0 is equivalent to the main
scenario where the device was unbiased for all individuals. The third scenario allowed bias in the device
to be defined by a function of an individual’s true Hb level to impose differential bias. The gradient of the
differential bias (the increase in bias per 1g/L increase in true Hb) was then varied. The bias for the ith
donor is given by bi = f(µi) = α + βµi, where α is the intercept and β is the gradient of the differential
bias. The functions were centred around the mean of the population’s true Hb level which keeps the mean
device bias equal to zero. β is varied between -0.5 and 0.5 and when the gradient is equal to zero, the bias
is equivalent to an unbiased device, i.e. the main scenario. The latter two scenarios were conducted since a
point-of-care device’s AUC is not sensitive to systematic bias but is affected by differential bias (Pfeiffer,
2017).
A further scenario altered the prevalence of low Hb by changing the baseline Hb distribution. This was
done by shifting each individual’s Hb level, and thus the mean Hb, by a fixed amount between -2g/L and
2g/L. By keeping the same Hb threshold the prevalence of low Hb is altered. The scenario was investigated
due to different populations having different levels of prevalence of low Hb.
5 Results
Population-level results for the simulation study main scenario based on an unbiased measurement device
are first shown before considering biases in the measurement device.
5.1 An unbiased measurement device
As the measurement error of the point-of-care device increases, the sensitivity and specificity drops
amongst all the testing strategies (Figure 2). The selective testing strategies (ST2 and ST3) are particularly
affected and give far worse sensitivity for all levels of measurement error, although due to the positive
bias exhibited in these strategies, the specificity is high. Strategies that take an average of two or three
measurements give better performance than the single measurement strategy for both sensitivity and
specificity. The STAM strategies have a sensitivity that lies between the AM and ST strategies.
The AUC is relatively high for all strategies when the standard deviation was ≤7g/L (Table 1). However,
as the standard deviation increases, the selective testing strategy with a maximum of three measurements
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gives the lowest AUC. With a standard deviation of 11g/L, there is a 10% relative difference in AUC
between the testing strategies ST3 and AM3. As expected, the STAM strategies give discriminative
performance that lies between the AM and ST strategies.
The mean bias in the estimated population Hb level in males is as high as 2.3g/L under strategy ST3
when the measurement error reaches 11g/L (Figure S1 and Table 1). These biases are not as extreme as
those estimated for an individual in Section 3 as the majority of donors in the population have Hb levels
sufficiently far away from the sex-specific donation threshold, which reduces the possibility of being
misclassified as having low or sufficient Hb. For example, 75% of male donors have Hb levels ≥10g/L
away (in absolute terms) from the donation threshold. The average measurement (AM) testing strategies
are shown to be unbiased for all levels of measurement error.
The coverage of the 95% confidence interval for the mean Hb level in the population is shown in Table
1, and also Figure S2 by the amount of measurement error present in the point-of-care test. The AM1,
AM2 and AM3 testing strategies have coverage equal to the nominal coverage rate (e.g. 95 per cent)
irrespective of measurement error, whilst the selective testing strategies (ST2, ST3, STAM2 and STAM3)
exhibit under-coverage and hence the confidence intervals will contain the true population mean less than
95% of the time. The coverage of ST3 is below 50% when the measurement error is >5g/L.
The variance of each of the testing strategies is shown in Figure S3. When the measurement error
increases it is trivial to see that the AM testing strategies has a variance equal to σ
2
e
K for K measurements.
The variance for the ST and STAM testing strategies decreases marginally when more measurements
are taken, however they are all similar regardless of how many measurements are taken. The reason
for this is that the majority of donors would only have one measurement if a ST or STAM strategy was
implemented, and thus the variances are all similar. Comparing the ST and STAM testing strategies with
the AM testing strategies show that the AM2 and AM3 testing strategies exhibit smaller variance for the
full range of measurement error shown, with the AM1 strategy showing a larger variance as it only takes
one measurement for all individuals.
Table 1 also shows that the mean standard error and the empirical standard error are similar across the
simulation scenarios and for all strategies suggesting that the drop in coverage for the selective testing
strategies arises due to the bias in the estimated population mean. The average number of measurements
taken per donor are equivalent for the ST and STAM strategies. Compared to AM3 where three
measurements are taken for all donors, both the ST3 and STAM3 strategies reduce the average number
of measurements per donor by 1.8.
5.2 A systematically biased measurement device
A plot of the sensitivity, specificity and AUC for each strategy is shown in Figure 3, when systematic bias
is introduced into the point-of-care device. The figure shows that a device that generally overestimates
Hb can cause a severe decrease in the sensitivity whilst marginally increasing the specificity. For example
given a low measurement error of 1g/L, a 2g/L increase in bias reduces the sensitivity from 90% to 60%
for ST2 whilst increasing the specificity by 2%. Likewise if a device underestimates Hb, the opposite is
true such that it increases the sensitivity whilst reducing the specificity. The changes in sensitivity and
specificity are less pronounced when using the AM testing strategy. The AUC is generally unaffected by
systematic bias, however there is a small decrease in AUC performance for both the ST and STAM testing
strategies when systematic bias is positive.
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5.3 Differential bias in measurement device
A plot of the sensitivity, specificity and AUC for each strategy when varying the between-person
standard deviation in the point-of-care device bias is shown in Figure 4. The figure shows that increasing
the between-person variability in bias reduces the AUC performance for any given strategy when the
measurement error is low. However, as the measurement error becomes larger and starts to dominate,
between-person variability has less of an effect. This can also be seen in the sensitivity as it converges the
larger the measurement error, and to a lesser effect for the specificity.
Figure 5 shows a plot of the three differential biases imposed based on true Hb level and how these affect
the sensitivity, specificity and AUC for each strategy. When the gradient of the bias is negative (i.e. the
point-of-care device is overestimating Hb for lower true Hb levels whilst underestimating for larger true
Hb levels) the sensitivity decreases relative to when the gradient is 0. Conversely the specificity is higher
when the gradient is negative. A sensitivity of 0% is seen when the measurement error is low and this is
due to the differential bias overestimating all individuals such that no individual is correctly identified as
a low Hb individual. The converse is true when the gradient of the bias is positive (i.e. the point-of-care
device is overestimating Hb for higher true Hb levels whilst underestimating for lower true Hb levels); the
sensitivity increases whilst the specificity decreases relative to when the gradient is 0. Therefore when the
gradient is positive the AUC increases relatively whilst when the gradient is negative the AUC decreases
dramatically.
5.4 Changing the baseline Hb distribution
The mean bias, sensitivity and specificity exhibited for the testing strategies is shown in Figure S4 for
different levels of true low Hb prevalence. Mean bias increases with prevalence and there is a greater
absolute difference in mean bias when the measurement error is large, for all selective testing strategies.
The figure shows that a change in prevalence does not drastically affect the magnitude of the mean bias,
with the greatest differences in mean bias occurring when the measurement error is very large. For
example, when the measurement error is at 11g/L the mean bias for the testing strategy ST3 is 2.3g/L
at the baseline prevalence of 5.3%. This increases by 0.4g/L when the prevalence increases to 8.1%, and
decreases by 0.4g/L when the prevalence decreases to 3.4%. The STAM testing strategies are less affected
by prevalence whilst the AM testing strategies all remain unbiased regardless of the prevalence rate. The
sensitivity and specificity is also relatively robust to changes in the prevalence for all strategies and amounts
of measurement error.
6 Discussion
This paper has shown that a selective testing (ST) strategy and a selective testing and averaging (STAM)
strategy can overestimate the decision-making Hb level at the individual-level, especially for individuals
close to the donation threshold. This has a consequence at the population-level where more individuals
are incorrectly bled below the threshold. The overestimation of the decision-making Hb level can
adversely affect the proportion of donors correctly identified as having a low Hb level (sensitivity) whilst
marginally increasing the proportion of donors correctly identified as having a sufficient Hb level to donate
(specificity).
Discriminatory performance is affected when using the selective testing strategies, whilst taking an
average of multiple measurements increases precision and thus increases discriminatory performance.
Further analyses, which changed the population prevalence, show that the prevalence of low Hb in the
population can affect the population-level mean bias by a small amount, however sensitivity and specificity
are largely unaffected by the changes in prevalence. Likewise changing the systematic bias of the device
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shows that the sensitivity and specificity can be affected. For example, using the AM1 and assuming a
measurement error of 11g/L, the sensitivity went from 68% to 60% when the bias of the point-of-care
device went from 0g/L to 2g/L.
The simulations show that a decrease in discriminative performance (as assessed using the AUC) is
dramatic when there is differential bias in the point-of-care device used, especially when the point-of-care
device overestimates low Hb and underestimates high Hb. This loss of discriminative performance is
further exacerbated by the testing strategy used.
Baart et al. (2016) recently used a selective testing strategy with a maximum of three measurements
(ST3) to assess the performance of three point-of-care devices in a population of blood donors in the
Netherlands. The sensitivity of these devices was found to be very low. The authors comment that results
were comparable with a single measurement strategy (AM1). This is contradictory to the findings in this
paper, which suggests sensitivity can suffer as a result of using a selective testing strategy.
It is recommended that a selective testing (ST) strategy is not used in practice due to the biases incurred for
donors close to the Hb threshold, and that an average of multiple measurements is the best strategy to use.
However, a STAM2 strategy may be considered as an alternative to the AM1 strategy, as it can increase
specificity and offer similar AUC performance but at a cost of some bias close to the threshold, a decrease
in sensitivity and overall coverage.
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7 Figures and Tables
ST2 ST3 STAM2 STAM3
−10 −5 0 5 10 −10 −5 0 5 10 −10 −5 0 5 10 −10 −5 0 5 10
0
2
4
6
Difference from Hb cut−off (g/L)
Bi
as
 (g
/L)
Measurement 
Error (g/L)
11 g/L
6 g/L
1 g/L
Figure 1 Bias exhibited at the individual-level for the selective testing strategies ST2, ST3, STAM2 and
STAM3 on a range of true Hb levels±10 g/L from the threshold T according to the amount of measurement
error; 1g/L in red, 6g/L in green and 11g/L in blue.
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Figure 2 Sensitivity and specificity with 95% binomial exact CI bands for each testing strategy according
to the amount of measurement error.
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Figure 3 Sensitivity, specificity and AUC exhibited for each testing strategy according to the amount of
systematic bias in the measurement device and the measurement error.
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Figure 4 Sensitivity, specificity and AUC exhibited for each testing strategy according to the amount
of between-person variability in the measurement device bias, given the average device bias is 0, and the
measurement error.
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Figure 5 Top: Differential biases with varying gradients that were imposed for each testing strategy. The
average device bias is 0 for all gradients. Bottom 3: The sensitivity, specificity and AUC exhibited for
each testing strategy, according to the amount of differential bias and the amount of measurement error.
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Strategy MeasurementError (g/L)
AUC %
(95% CI)
Coverage
(%)
Mean Bias
(g/L)
SE (g/L) Average No.
MeasurementsMean Empirical
1 99.9 (99.8, 100.0) 95.0 0.03 0.20 0.20 1.06
3 99.0 (98.6, 99.4) 90.3 0.13 0.21 0.21 1.06
ST2 5 96.9 (96.0, 97.9) 65.5 0.34 0.22 0.22 1.08
7 94.0 (92.4, 95.6) 13.8 0.71 0.23 0.23 1.10
9 90.8 (88.5, 92.3) 0.1 1.22 0.25 0.25 1.12
11 87.5 (84.7, 90.2) 0.0 1.86 0.27 0.27 1.14
1 99.9 (99.8, 100.0) 94.8 0.04 0.20 0.20 1.11
3 98.8 (98.4, 99.3) 86.8 0.17 0.21 0.21 1.11
ST3 5 96.5 (95.5, 97.5) 44.8 0.45 0.21 0.21 1.12
7 93.2 (91.5, 94.9) 2.0 0.90 0.22 0.22 1.14
9 89.5 (87.1, 91.8) 0.0 1.53 0.24 0.24 1.16
11 85.9 (83.0, 88.7) 0.0 2.33 0.25 0.27 1.19
1 99.9 (99.8, 100.0) 94.6 0.02 0.20 0.20 1.00
3 99.0 (98.6, 99.3) 94.4 0.02 0.21 0.21 1.00
AM1 5 97.0 (96.2, 97.9) 94.6 0.02 0.22 0.23 1.00
7 94.3 (92.9, 95.8) 94.8 0.02 0.24 0.25 1.00
9 91.2 (89.2, 93.2) 94.6 0.02 0.27 0.27 1.00
11 88.0 (85.5, 90.5) 94.3 0.02 0.30 0.30 1.00
1 99.9 (99.9, 100.0) 94.8 0.02 0.20 0.20 2.00
3 99.5 (99.3, 99.7) 95.2 0.02 0.21 0.20 2.00
AM2 5 98.5 (98.0, 99.0) 95.7 0.02 0.21 0.21 2.00
7 97.1 (96.3, 98.0) 96.0 0.02 0.22 0.22 2.00
9 95.3 (94.0, 96.5) 96.0 0.02 0.24 0.23 2.00
11 93.2 (91.5, 94.8) 95.9 0.03 0.25 0.25 2.00
1 100.0 (99.9, 100.0) 94.8 0.02 0.20 0.20 3.00
3 99.7 (99.5, 99.8) 94.8 0.02 0.20 0.20 3.00
AM3 5 99.0 (98.7, 99.4) 94.9 0.02 0.21 0.21 3.00
7 98.1 (97.5, 98.7) 95.3 0.03 0.22 0.21 3.00
9 96.8 (95.9, 97.7) 95.9 0.03 0.23 0.22 3.00
11 95.3 (94.0, 96.5) 95.7 0.03 0.24 0.23 3.00
1 99.9 (99.9, 100.0) 94.8 0.03 0.20 0.20 1.06
3 99.2 (98.8, 99.5) 93.5 0.07 0.21 0.21 1.06
STAM2 5 97.5 (96.7, 98.4) 86.2 0.18 0.22 0.22 1.08
7 95.1 (93.7, 96.6) 66.0 0.36 0.23 0.24 1.10
9 92.4 (90.3, 94.4) 30.8 0.62 0.25 0.25 1.12
11 89.5 (86.9, 92.0) 7.6 0.94 0.27 0.27 1.14
1 99.9 (99.9, 100.0) 94.8 0.03 0.20 0.20 1.11
3 99.2 (98.8, 99.5) 92.9 0.09 0.21 0.21 1.11
STAM3 5 97.6 (96.7, 98.4) 83.6 0.22 0.22 0.22 1.12
7 95.2 (93.8, 96.7) 55.0 0.43 0.23 0.23 1.14
9 92.5 (90.5, 94.5) 17.7 0.72 0.25 0.25 1.16
11 89.6 (87.1, 92.2) 1.6 1.10 0.27 0.27 1.19
Table 1 Comparison of AUC performance, coverage, mean bias, as well as the mean SE and empirical
SE for the testing strategies. The average number of measurements for a population of donors using each
testing strategy is also recorded, as the measurement error is varied between 1g/L and 11g/L
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